Patents by Inventor Marcus G. Grodberg

Marcus G. Grodberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5286490
    Abstract: A transdermal fluoride medication for providing fluoride ion for the prevention and treatment of bone loss disease, which may have an estrogen-containing substance for not only treating hormonal imbalance but to obtain more advantageous use of the fluoride ion within the body. A transdermal enhancer is present. The preferred form is a transdermal patch containing sodium monofluorophosphate and further optionally including an estrogen-containing substance and a transdermal enhancer, which is adhesively attached on the skin of the patient for slow release of fluoride ion and, optionally, estrogen to the bloodstream of the patient. Up to ten percent of sodium fluoride and/or calcium can be added.
    Type: Grant
    Filed: May 4, 1990
    Date of Patent: February 15, 1994
    Assignee: Colgate-Palmolive Company
    Inventor: Marcus G. Grodberg
  • Patent number: 5156845
    Abstract: A dry mouth lozenge comprising a base, a pharmaceutically acceptable acedulate, such as a natural sweetener, betaine hydrochloride and a phramaceutically acceptable fluoride.
    Type: Grant
    Filed: May 4, 1990
    Date of Patent: October 20, 1992
    Assignee: Colgate-Palmolive Company
    Inventor: Marcus G. Grodberg
  • Patent number: 5153005
    Abstract: A fluorosis-free ingestible fluoride ion-containing composition comprising a mixture of pharmaceutically acceptable fluoride and monofluorophosphate in a weight ratio to provide not more than about fifty percent, and preferably not more than about twenty-five percent, of available fluoride ion from the fluoride and the balance from the monofluorophosphate. By "fluorosis-free" composition is meant one which, when ingested, minimizes or obviates the occurrence of fluorosis which is a common effect when fluoride is ingested. The composition may contain additional pharmaceutically acceptable adjuvants, such as vitamins, coloring, flavoring, carriers, stabilizers, preservatives, medicants and the like, and may be in the form of a powder, tablet, capsule, pill or a liquid in a suitable ingestible carrier. Preferred compounds are alkali metal, ammonium and amine fluorides and monofluorophosphates. Most preferred compounds are sodium fluoride (NaF) and sodium monofluorophosphate (MFP), whose formula is Na.sub.2 FPO.
    Type: Grant
    Filed: December 11, 1990
    Date of Patent: October 6, 1992
    Assignee: Colgate-Palmolive Company
    Inventor: Marcus G. Grodberg
  • Patent number: 5039526
    Abstract: A buccal lozenge medication for providing fluoride ion for the prevention and treatment of bone loss disease. The dosage is a lozenge containing from 20 to 100 milligrams of sodium monofluorophosphate and further including a slow release mechanism for controlling release of the fluoride ion while in the mouth. Up to ten percent of sodium fluoride can be added.
    Type: Grant
    Filed: April 16, 1990
    Date of Patent: August 13, 1991
    Assignee: Colgate-Palmolive Company
    Inventors: Marcus G. Grodberg, David J. Baylink
  • Patent number: 5013728
    Abstract: A medication for providing fluoride ion for the prevention and treatment of bone loss disease, together with an estrogen-containing substance for not only treating hormonal imbalance but to obtain more advantageous use of the fluoride ion within the body. The dosage is a lozenge, tablet or capsule containing from 20 to 100 milligrams of sodium monofluorophosphate and further including an estrogen-containing substance and a slow release mechanism for controlling release of the fluoride ion and estrogen over a period of from four to eight hours after swallowing. Up to ten percent of sodium fluoride and/or calcium can be added.
    Type: Grant
    Filed: May 4, 1990
    Date of Patent: May 7, 1991
    Assignee: Colgate - Palmolive Company
    Inventor: Marcus G. Grodberg
  • Patent number: 4861590
    Abstract: A slow release tablet or the like for releasing fluoride and calcium ions in a manner so as to reduce the formation of calcium fluoride and to reduce gastrointestinal discomfort comprising the use of MFP together with a calcium-containing composition.
    Type: Grant
    Filed: September 25, 1986
    Date of Patent: August 29, 1989
    Assignee: Colgate-Palmolive Company
    Inventor: Marcus G. Grodberg
  • Patent number: 4859467
    Abstract: A medication for providing fluoride ion for the prevention and treatment of bone loss disease. The dosage is a lozenge, tablet or capsule containing from 20 to 100 milligrams of sodium monofluorophosphate and further includes a slow release mechanism for controlling release of the fluoride ion over a period of up to eight hours after swallowing. Up to ten percent of sodium fluoride can be added.
    Type: Grant
    Filed: September 25, 1986
    Date of Patent: August 22, 1989
    Assignee: Colgate-Palmotive Company
    Inventors: Marcus G. Grodberg, David J. Baylink